Wall Street Zen Upgrades Precipio (NASDAQ:PRPO) to Hold

Precipio (NASDAQ:PRPO) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Precipio in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Precipio has an average rating of “Sell”.

Precipio Trading Up 4.3%

NASDAQ:PRPO opened at $23.39 on Friday. Precipio has a 12-month low of $3.90 and a 12-month high of $28.50. The firm has a market cap of $40.98 million, a PE ratio of -28.52 and a beta of 1.20. The company has a current ratio of 1.27, a quick ratio of 1.10 and a debt-to-equity ratio of 0.06. The stock has a fifty day moving average price of $23.60 and a 200 day moving average price of $20.42.

Precipio (NASDAQ:PRPO) last posted its quarterly earnings results on Friday, November 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter. The company had revenue of $6.77 million during the quarter. Precipio had a negative net margin of 5.50% and a negative return on equity of 10.07%.

Hedge Funds Weigh In On Precipio

Hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC raised its holdings in Precipio by 10.7% during the fourth quarter. Renaissance Technologies LLC now owns 14,500 shares of the biotechnology company’s stock worth $333,000 after purchasing an additional 1,400 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Precipio by 5.1% in the 4th quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after buying an additional 789 shares during the last quarter. Susquehanna International Group LLP acquired a new stake in Precipio during the 3rd quarter worth $194,000. Topline Capital Management LLC acquired a new stake in Precipio during the 3rd quarter worth $1,158,000. Finally, Evernest Financial Advisors LLC purchased a new stake in Precipio in the third quarter valued at $374,000. 10.45% of the stock is currently owned by hedge funds and other institutional investors.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.